Vanguard Group Inc Chimerix Inc Transaction History

Vanguard Group Inc

$5.12 Trillion
Q2 2024

A detailed history of Vanguard Group Inc transactions in Chimerix Inc stock. As of the latest transaction made, Vanguard Group Inc holds 4,345,579 shares of CMRX stock, worth $4 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

4,345,579

Previous 4,345,579 -0.0%

Holding current value

$4 Million

Previous $4.61 Million 16.98%

% of portfolio

0.0%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$0.94 - $1.23 $148,253 - $193,991	157,717 Added 3.77%	4,345,579 $4.17 Million
Q2 2023 Aug 14, 2023	SELL	$1.1 - $1.54 $404,704 - $566,586	-367,913 Reduced 8.08%	4,187,862 $5.07 Million
Q1 2023 May 15, 2023	BUY	$1.19 - $2.09 $385,003 - $676,181	323,532 Added 7.64%	4,555,775 $5.74 Million
Q4 2022 Feb 10, 2023	SELL	$1.67 - $2.35 $430,584 - $605,912	-257,835 Reduced 5.74%	4,232,243 $7.87 Million
Q3 2022 Nov 14, 2022	BUY	$1.81 - $2.76 $1.13 Million - $1.72 Million	623,268 Added 16.12%	4,490,078 $8.67 Million
Q2 2022 Aug 12, 2022	BUY	$1.34 - $5.34 $46,307 - $184,539	34,558 Added 0.9%	3,866,810 $8.04 Million
Q1 2022 May 13, 2022	BUY	$4.58 - $6.8 $482,919 - $716,998	105,441 Added 2.83%	3,832,252 $17.6 Million
Q4 2021 Feb 14, 2022	BUY	$5.23 - $7.18 $1.06 Million - $1.45 Million	201,749 Added 5.72%	3,726,811 $24 Million
Q3 2021 Nov 12, 2021	SELL	$5.94 - $8.75 $374,320 - $551,398	-63,017 Reduced 1.76%	3,525,062 $21.8 Million
Q2 2021 Aug 13, 2021	BUY	$7.54 - $9.79 $27.1 Million - $35.1 Million	3,588,079 New	3,588,079 $28.7 Million

Others Institutions Holding CMRX

# of Institutions

Shares Held

36.8M

Call Options Held

72.2K

Put Options Held

169K

View Full List

About CHIMERIX INC

Ticker CMRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 87,622,896
Market Cap $80.6M
Description
Chimerix, Inc., a biopharmaceutical company, develops medicines to enhance the lives of patients living with serious diseases. The company's approved product is TEMBEXA (brincidofovir), a lipid conjugate through inhibition of viral DNA synthesis that is developed as a medical countermeasure for smallpox. Its clinical stage development programs i...

More about CMRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.

Account

Vanguard Group Inc Chimerix Inc Transaction History